FUTERMESTOTUG
UNII LSX3UPC7JY

Substance Identification & Data

This profile provides standardized clinical and technical data for Futermestotug, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LSX3UPC7JY.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3014361-57-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LSX3UPC7JY

CAS Registry Number

3014361-57-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

FUTERMESTOTUG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C176873

National Cancer Institute reference terminology for clinical and research data.

INN ID

13465

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-36

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Futermestotug. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

FUTERMESTOTUG

Common Names & Synonyms

FUTERMESTOTUG [INN]

FUTERMESTOTUG [USAN]

H-GAMMA1 HEAVY CHAIN HUMANIZED (1-452) (VH (HOMO SAPIENS IGHV3-23*04 (90.8%) -(IGHD) -IGHJ4*01 (80.0%) S128>A (122), CDR-IMGT (8.8.15) (26-33.51-58.97-111)) (1-122) -HOMO SAPIENS IGHG1*03V (100%) G1M3>G1M17, NG1M1 CH1 K120, CH3 E12, M14 (CH1 R120>K (219) (123-220), HINGE 1-15 (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)), (225-214')-DISULFIDE WITH LKAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-9*01 (85.3%) -IGKJ4*01 (90.9%) V124>L (104'), CDR-IMGT (6.3.9) (27'-32'.50'-52'.89'-97')) (1'-107') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')); DIMER (231-231'':234-234'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

IMMUNOGLOBULIN G1, ANTI-(HUMAN/MACACA MULATTA CTLA-4 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL YH001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL YH001 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4, CTLA-4, CD152)), HUMANIZED MONOCLONAL ANTIBODY;

RECOMBINANT HUMANIZED ANTI-CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (ANTI-CTLA4) IGG1 MONOCLONAL ANTIBODY

YH 001 [WHO-DD]